ASH 2019: Successful and safe treatment of intestinal Graft-versus-Host Disease (GvHD) with pooled-donor full ecosystem microbiota therapeutics - MaaT Pharma

See More

Previous PostMaaT Pharma Announces €18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics
Next PostMaaT Pharma announces the presentation of data with its Lead Microbiota Biotherapeutic in intestinal GvHD at 61st American Society of Hematology (ASH) Annual Meeting

© 2022 MaaT Pharma. MaaT Pharma’s mission is to restore microbiome function to treat life-threatening diseases

MaaT Pharma dans les médias MaaT Pharma in the News